PA
TYRA icon

Profund Advisors’s Tyra Biosciences TYRA Stock Holding History

Profund Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$626K Buy
19,588
+3,932
+25% +$130K 0.02% 475
2026
Q1 		$600K Buy
+15,656
New +$507K 0.02% 489

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Profund Advisors's TYRA Position: Q2 2026 in Review

Profund Advisors increased its Tyra Biosciences (TYRA) stake by 25% in Q2 2026, buying an estimated $130K and bringing the position to 19,588 shares worth $626K. The position accounts for 0.02% of the portfolio, ranked #475.

Profund Advisors first reported a position in TYRA in Q1 2026 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Profund Advisors held 19,588 shares of Tyra Biosciences worth $626K as of Q2 2026.
  • Profund Advisors bought 3,932 Tyra Biosciences shares in Q2 2026, an estimated $130K.
  • Tyra Biosciences made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #475 holding.
  • Profund Advisors first reported a position in Tyra Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.